COVID-19 Clinical Update | May 18, 2022
Date of Presentation: May 18, 2022
Type: Past Presentation
Audience: Clinical
Program: Virology
Keywords: #covid #covid clinical updates #covid treatment
In this presentation, Dr. Jorge Mera, ECHO Medical Director and Director of Infectious Diseases for Cherokee Nation Health Services, discusses the latest COVID-19 clinical updates, epidemiology, variants, treatments and vaccine updates.
Recording:
Presented by:
Dr. Jorge Mera
Dr. Jorge Mera is the Director of Infectious Diseases for Cherokee Nation Health Services (CNHS), the largest tribally operated health care system in the United States. He completed his fellowship in Infectious Diseases and Clinical Microbiology at Baylor College of Medicine in Houston, Texas and is Board Certified by the American Board of Internal Medicine (ABIM) in Infectious Diseases. During recent years Jorge’s efforts have been dedicated to organizing the Cherokee Nation HCV elimination program, as well as the HIV/HCV ECHO project. He is also the Director of the HIV clinic since 2012 and the Principal Investigator of the End the HIV Epidemic for the CNHS. He is a Clinical Assistant Professor in the Department of Internal Medicine of the Oklahoma State University Health Science Center and a Fellow of the American College of Physicians.
Resources Provided:
- To Claim CE
- Monitoring Variant Proportions (CDC)
- COVID Data Tracker: Trends in Cases and Deaths (CDC)
- Clinical Spectrum of SARS-CoV-2 Infection (NIH)
- Lab-Confirmed COVID-19–Associated Hospitalization Rates Stratified by Age (COVID-NET)
- Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series (MMWR)
- COVID-19 Treatment Guidelines: Clinical Management Summary (NIH)
- COVID Deaths (NYtimes)
- Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses (Lancet)
- Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting (NEJM)
- FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years (FDA)
- Therapeutic Management of Hospitalized Adults With COVID-19 (NIH)
- UPMC OPTIMISE-C19 Trial, a COVID-19 Study (Clinical Trials)
- The UPMC OPTIMISE-C19 trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization (TrialsJournal)
- SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity (Cell Report)
- PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers (FDA)
- COVID-19 Clinical Update (Presentation Slides)
Date added: May 19, 2022